NCT07934017

A Study of SL-325 in Participants With Hidradenitis Suppurativa

StatusNot Yet Recruiting

PhasePhase 2

SponsorShattuck Labs, Inc.

Primary completionFeb 2028 (estimated)

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

Notable Nov 12, 2026 Eligibility criteria changed
Nov 6, 2026 Study First Submitted

Notable: the plan changed

Endpoints

Primary

Proportion of participants achieving HiSCR50

Timeframe: Week 16

Secondary (3)

Proportion of participants achieving HiSCR75

Incidence and severity of treatment-emergent adverse events

Number of participants who discontinue study intervention due to an TEAE

Arms and interventions

SL-325 high doseExperimental

SL-325 low doseExperimental

PlaceboPlacebo comparator

Drugs: SL-325, Placebo

About this trial

The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with Hidradenitis Suppurativa. The study consists of a screening period of up to 5 weeks, a 16-week primary treatment period, 36-week extension period, and a follow-up period of up to 12 weeks.

Trial details

Enrollment: 150 participants (estimated)
Started: Jan 2027
Study completion: Dec 2028 (estimated)
Eligibility: 18 and older, all sexes, no healthy volunteers
Design: Interventional, randomized, quadruple blind, treatment
Oversight: Data monitoring committee, FDA-regulated drug
Conditions: Hidradenitis Suppurativa, Hidradenitis Suppurativa (HS)
Official title: A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SL-325 in Participants With Moderate to Severe Hidradenitis Suppurativa (RECEPTIVE-HS1)
First posted: Nov 12, 2026
Registry updated: Nov 13, 2026
Last verified: Nov 2026

Related trials at risk

View on ClinicalTrials.gov ↗